A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan

Table 3 The demographic and comorbid medical disorders at index date after propensity score weighting among hypertensive and diabetic patients who were prescribed with either angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) stratified by chronic kidney disease or not

	Propensity score weighting
	With CKD			Without CKD
	ACEi (n = 932)	ARB (n = 2135)	Standardized mean difference	ACEi (n = 5966)	ARB (n = 10,623)	Standardized mean difference
Duration from DM to index date (years)	3.50 ± 3.33	3.52 ± 2.09	−0.0049	3.00 ± 3.11	3.01 ± 2.29	−0.0035
Age (years) (mean ± SD)	65.5 ± 13.3	65.2 ± 8.8	0.0276	60.8 ± 12.9	60.6 ± 9.8	0.0175
Age group (years)			0.0123			0.0049
20–49 (%)	14.70	15.06		21.81	21.92
50–64 (%)	32.08	32.25		40.56	40.69
65+ (%)	53.22	52.69		37.63	37.39
Male sex	59.12 %	59.21 %	−0.0019	59.52 %	59.62 %	−0.0019
Congestive heart failure	8.05 %	8.15 %	−0.0039	3.96 %	3.94 %	0.0006
Stroke	16.20 %	16.15 %	0.0014	12.19 %	12.16 %	0.0007
Malignant dysrhythmia	0.21 %	0.21 %	0.0014	0.49 %	0.48 %	0.0011
Cardiogenic shock	0.64 %	0.73 %	−0.0102	0.27 %	0.27 %	−0.0011
MI/PCI	5.15 %	5.08 %	0.0030	4.98 %	4.96 %	0.0008
CABG	0.11 %	0.11 %	−0.0010	0.52 %	0.51 %	0.0008
Thrombolysis therapy	0.00 %	0.00 %	−0.0002	0.28 %	0.28 %	0.0012
Hyperlipidemia	59.44 %	59.86 %	−0.0085	53.77 %	53.77 %	−0.0017
Incidence of ESRD^a	1.39	2.34		0.30	0.37
(95 % CI)	(1.00−1.78)	(1.80−2.89)		(0.23−0.37)	(0.29−0.46)

DM diabetes mellitus, ACEi angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, CKD chronic kidney diseases, MI myocardial infarction, PCI percutaneous coronary intevention, CABG coronary artery bypass graft surgery
^aIncidence per 100 person-years

ISSN: 1475-2840